Welcome to our dedicated page for Pharvaris news (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris stock.
Pharvaris N.V. reports developments as a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases, including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency. Its lead program, deucrictibant, is being developed in immediate-release capsule and extended-release tablet forms for on-demand and prophylactic treatment settings.
Recurring updates include clinical data from the RAPIDe and CHAPTER study programs, patient-reported outcome research, scientific publications, presentations at allergy and immunology meetings, financial results, strategic priorities, shareholder voting matters and capital-structure disclosures.
Pharvaris (Nasdaq: PHVS) has appointed Dr. Elisabeth Björk to its board of directors, effective December 1, 2021, to strengthen its leadership ahead of anticipated Phase 2 clinical data releases for hereditary angioedema (HAE) treatments. Dr. Björk, a seasoned expert in drug development at AstraZeneca, is set to replace Martijn Kleijwegt, who stepped down to focus on new investments. This leadership change aims to enhance Pharvaris’s capabilities as it prepares for commercialization of its bradykinin-B2-receptor antagonists candidates, PHVS416 and PHVS719, in the upcoming years.
Pharvaris (Nasdaq: PHVS) continues its robust clinical development with two Phase 2 studies for PHVS416 aimed at treating hereditary angioedema (HAE). The RAPIDe-1 study for on-demand treatment is progressing, while the CHAPTER-1 study for prophylactic treatment is now recruiting patients. Additionally, a Phase 1 pharmacokinetics study for PHVS719 is set to begin this month. Financially, Pharvaris reported cash and equivalents of €218.6 million as of September 30, 2021, marking a significant increase from €98.6 million at year-end 2020. However, R&D expenses rose to €9.0 million, and the quarterly loss was €9.1 million.
Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on novel oral bradykinin-B2-receptor antagonists, announced its participation in three investor conferences in September 2021. These include the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21. Live audio webcasts will be available on their website, with replays for 30 days following each event.
Pharvaris (Nasdaq: PHVS) reported significant advancements in its clinical programs for PHVS416, a treatment for hereditary angioedema (HAE). The Phase 2 RAPIDe-1 on-demand study is expanding into the US, with data expected in 2022. Additionally, the Phase 2 CHAPTER-1 study for prophylaxis is set to begin in 2021. Financially, the company holds €224.3 million in cash as of June 30, 2021, despite reporting a €15.2 million loss for the quarter. The increase in R&D and G&A expenses highlights the company's growth strategy and investment in clinical studies.
Pharvaris (Nasdaq: PHVS) presented clinical data supporting the safety and pharmacokinetic profile of PHA121 for hereditary angioedema (HAE) at the EAACI Annual Congress 2021. In a double-blind, placebo-controlled study involving 38 healthy volunteers, PHA121 was well-tolerated, with all treatment-emergent adverse events classified as mild. The drug demonstrated dose-proportional absorption with steady-state plasma levels achieved within three days. Pharvaris aims to develop PHA121 into an effective oral treatment for HAE alongside formulations PHVS416 and PHVS719.
Pharvaris (Nasdaq: PHVS) announced the presentation of clinical data for oral PHA121, a bradykinin B2 receptor antagonist for hereditary angioedema (HAE), at the EAACI Annual Congress 2021, from July 10-16. The e-Poster will detail the pharmacokinetic profile and tolerability of PHA121 in multiple dose administration. The abstract will be available on the EAACI website on July 10. Pharvaris focuses on developing oral treatments for HAE, aiming to provide alternatives to injected therapies.
Pharvaris (Nasdaq: PHVS) announced its annual general meeting of shareholders scheduled for June 29, 2021, at 1:00 p.m. CEST. Relevant documents, including the notice and agenda, will be accessible in the 'Investors' section of Pharvaris’ website and on the SEC’s site. Pharvaris is focused on developing oral bradykinin-B2-receptor antagonists aimed at treating hereditary angioedema (HAE) and related conditions, offering alternatives to injected therapies. The company's leadership comprises experts in pharmaceutical development and rare disorders.
Pharvaris (Nasdaq: PHVS) announced at the 12th C1 Inhibitor Deficiency and Angioedema Workshop that its compound PHA121 demonstrates superior pharmacokinetic and pharmacodynamic profiles compared to icatibant for hereditary angioedema (HAE) treatment. Dr. Anne Lesage highlighted findings from bradykinin challenge data indicating faster onset and longer duration of effect. Pharvaris is advancing PHA121 for both on-demand and prophylactic treatments, with formulations PHVS416 and PHVS719 in various stages of clinical development.
Pharvaris (PHVS) reported a strong financial position with cash and equivalents of €238.3 million as of March 31, 2021. The company is advancing its Phase 2 studies for PHVS416, an oral treatment for hereditary angioedema (HAE), with the RAPIDe-1 on-demand study underway and the HAE CHAPTER-1 prophylactic study set to initiate in 2021. The leadership team has expanded with the appointment of Wim Souverijns as chief community engagement & commercial officer and the nomination of Viviane Monges to the Board of Directors.
Pharvaris (Nasdaq: PHVS) has appointed Wim Souverijns, Ph.D., as Chief Community Engagement & Commercial Officer, effective July 1, 2021. With over 25 years of experience in pharmaceutical leadership, Souverijns will enhance Pharvaris' engagement with the HAE community and support the commercialization of PHVS416 and PHVS719. This strategic appointment aims to bolster the company's clinical development programs and market readiness for its oral bradykinin-B2-receptor antagonists. Pharvaris focuses on innovative treatments for hereditary angioedema (HAE).